Promomed Group registered its first RNA drug Radamin® Viro

Promomed 20 January 2022

Promomed Group received a marketing authorization certificate for its first biological product. The active ingredient of the new drug is sodium salt of double-stranded RNA that stimulates the production of all major types of interferons, triggering an adequate innate and adaptive immune response, which ensures the rapid onset of the therapeutic effect and the protection against various viral and bacterial infections.

«Promomed Group expanded the area of research interest beyond the limits of chemical synthesis, turning to biotechnology. The company’s specialists were able to recreate the developments that Soviet scientists were working on and improve them with the help of biotechnological innovations. Biological preparations have made a breakthrough in the treatment of many diseases. Development of Radamin® Viro is the first step that opens a new chapter in the history of the company, dedicated to the creation of fundamentally new methods for the treatment of major diseases,» commented Kira Zaslavskaya, Director for New Products at Promomed Group.

After administration, Radamin® Viro stimulates the formation of endogenous interferons that have anti-inflammatory, immunostimulating, antiviral and other activities that provide a natural protective response of the body. It is very important that the immune response occurs quickly, within 2-6 hours after the use of the drug, while within two days the level of interferons returns to its background values.

«The urgent need to develop new methods of etiotropic therapy, as well as increasing drug resistance of microorganisms, made the search for agents that provide an adequate immune response very important. The most promising is the creation of drugs that activate the first line of defense in the body, the interferon system. It prevents the penetration of pathogen into cell, disrupts the reproduction of viruses and starts the processes leading to the elimination of the pathogenic agent from the body,» commented Olga Radaeva, allergist-immunologist, Doctor of Medical Sciences, Professor, Head of the Department of Immunology, Microbiology and Virology of the Medical Institute of the Ogarev Mordovia State University.

The absence of mutagenic, allergic, cumulative and local irritating effects of Radamin® Viro, as well as the effect on reproductive function, ensures a high level of drug safety.

The drug product is available in the form of lyophilisate for the preparation of solution for intramuscular and subcutaneous administration with a dosage of 5 mg, 2, 3, 4 or 5 vials per pack, which corresponds to the current treatment regimens.